

Special Issue

Vaccine Development for Viral Infection

Message from the Guest Editors

The SARS-CoV-2 pandemic has stimulated vaccine research and accelerated the development of innovative vaccine strategies. These vaccines appear essential to protect against severe forms of COVID-19 and to help to mitigate the global impact of SARS-CoV-2. While some viral diseases have been easily controlled and some eradicated by vaccines, there are still many viruses against which the development of an effective vaccine remains a dream. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: epidemiological, biological, and clinical aspects related to already existing vaccines as well as advances in the development of new vaccines against viral infections, especially against the ones that currently do not have any vaccine available, e.g., other respiratory viruses such as RSV, viruses of the immunocompromised such as Polyomaviruses, or other global pandemics such as HIV. Vaccines against emerging viruses and current vaccines improvements are also welcomed themes.

Guest Editors

Dr. Morgane Solis

Virology Laboratory, Strasbourg University Hospitals, 67000 Strasbourg, France

Dr. Minhui Guan

MU Center for Influenza and Emerging Infectious Diseases, University of Missouri, Columbia, MO 65211, USA

Deadline for manuscript submissions

closed (12 July 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/110123

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).